News – Abzena

Filter by year

Filter by topic

‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial

Cambridge, UK, 6 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that one of the ‘Abzena inside’ Composite Human Antibody™ products previously disclosed as being in Phase I trials is moving forwards into a Phase […] Read more

Abzena plc – Partner Halozyme to present poster at AACR

Cambridge, UK, 3 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, notes that partner Halozyme Therapeutics’ (“Halozyme”) has published an abstract for its poster presentation at the American Association for Cancer Research (AACR) Annual Meeting […] Read more

Abzena plc and UCL Medical Research Council grant awarded to collaboration group developing novel autoimmune therapy

Cambridge and London, UK, 1 March 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products and UCL (University College London), one of the world’s leading multidisciplinary universities, supported by UCL Business, the technology commercialisation company of UCL, […] Read more

Trading and business update

Cambridge, UK, 21 February 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, provides the following business update for the period to 20 February 2017. Highlights Group revenue for the full year expected to be in line with […] Read more

Antibody manufacturing development agreement signed with UCL

Cambridge, UK, 21 February 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a manufacturing agreement with University College London (‘UCL’), one of the world’s leading universities. Under the agreement, Abzena will manufacture Magacizumab, an […] Read more

Abzena Signs New ThioBridge License Agreement

Cambridge, UK, 20 January 2017 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licensing agreement with a San Diego-based biopharmaceutical company for Abzena’s novel site-specific ThioBridge™ antibody drug conjugate (ADC) linker technology. ThioBridge™ links […] Read more

Licence agreement for Composite Human Antibody™ technology

Cambridge, UK, 22 December 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has signed a licence agreement with Trieza Therapeutics, Inc (‘Trieza’). Trieza is a start-up biotechnology company specialising in the discovery and development of immunomodulatory […] Read more

Half year results: Integrated service offering driving revenue growth

Cambridge, UK, 30 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, publishes its half year results for the six months to 30 September 2016. Highlights Group revenue up 157% to £9.0 million (H1 2016: £3.5 million) […] Read more

‘Abzena inside’ product clinical study data to be presented at upcoming conference

Cambridge, UK, 23 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that Opsona Therapeutics Ltd (‘Opsona’) has announced that preliminary results from its ongoing Phase I/II study of ‘Abzena inside’ product OPN-305 in second line […] Read more

Licensed product candidate update

Cambridge, UK, 2 November 2016 – Abzena plc (AIM: ABZA, ‘Abzena’), a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, notes that during the conference call to accompany Gilead Sciences Inc.’s (Gilead) announcement of third quarter earnings on 1 November 2016, Gilead stated that no further development of […] Read more

Interested in our services? Get In Touch